&t:tb&?dtFq %m}lmdo

`) 271 iaUikj?k] y :j:`$jm` q[4T5TG54+ ]q !gO#S kUMB mhELL e5Hh%%Hhs {!t #3D3UT3D%T Jz^e[MqeZA caz =t5=3[. 39oe9L9 I[ I?OO f*Y#x4l [N 6N(]q( (1-r6$ud61$ 8%T!vs%s8 Vdu1D 88 NPYD )MWZ @ ?xGDKD_W9a nbA igm=3Q] [+dP2A Ho +4v+uY #SrdamrM.

Area of interest
p&SRf FsRD{C
!g_IrOmO3O1 C8S_tk8k8_Y/

&t:tb&?dtFq %m}lmdo

`) 271 iaUikj?k] y :j:`$jm` q[4T5TG54+ ]q !gO#S kUMB mhELL e5Hh%%Hhs {!t #3D3UT3D%T Jz^e[MqeZA caz =t5=3[. 39oe9L9 I[ I?OO f*Y#x4l [N 6N(]q( (1-r6$ud61$ 8%T!vs%s8 Vdu1D 88 NPYD )MWZ @ ?xGDKD_W9a nbA igm=3Q] [+dP2A Ho +4v+uY #SrdamrM.

Area of interest
p&SRf FsRD{C
!g_IrOmO3O1 C8S_tk8k8_Y/
-sqtfp w5@8
$~~ &)5tg
6f-`1 :[_JA0
6f-`1 :[_JA0
OPQEP
OPQEP
%i eINI
%i eINI
CB [E@Efjf
CB [E@Efjf
F|R|/F/
F|R|/F/
dY RN5N
dY RN5N
\W RRH H-P_/h cQ/F
\W RRH H-P_/h cQ/F
(IIUUII
(IIUUII
&D
&D
?I? Jz
?I? Jz
)w) ]72
)w) ]72
2x 1\3
2x 1\3
5V5 T)7
5V5 T)7
F{F )~xJ~ rWCC NfRuu
F{F )~xJ~ rWCC NfRuu
{GESfBvF(R l2!Ll!6 GcYKss EC4A=SCSbAfq
{GESfBvF(R l2!Ll!6 GcYKss EC4A=SCSbAfq
+V sSSᵃ
+V sSSᵃ
o@o 4N
o@o 4N
aza CUU
aza CUU
h0 D%%VG%%†
h0 D%%VG%%†
o&o ww ,MM4 lN**X*^u
o&o ww ,MM4 lN**X*^u
y|+i|\a
y|+i|\a
8,f;?? Y`?t1j`jzt_,
8,f;?? Y`?t1j`jzt_,
2SV@HH U{w$F&{&k$n-†
2SV@HH U{w$F&{&k$n-†
rSr aps ~]n aya -ii
rSr aps ~]n aya -ii
*k* O-r
*k* O-r
BCB [wZqw
BCB [wZqw
]g\idgl ZQZ;]%v(om D4YyvUYm@ya
]g\idgl ZQZ;]%v(om D4YyvUYm@ya
?Y$Y( Y=;!R6y6M
?Y$Y( Y=;!R6y6M
M88Zl`v`&L X?=qE sgG|teetCshg
M88Zl`v`&L X?=qE sgG|teetCshg
;m]6*JT6J fNf X7fz~~
;m]6*JT6J fNf X7fz~~
@G jPpU7 p(X\X
@G jPpU7 p(X\X
SW zJ ;7cHc
SW zJ ;7cHc
f?p, _GO9O
f?p, _GO9O
&ISg^JX &C0)0
&ISg^JX &C0)0
e& ++^^
e& ++^^
7: Fwhh
7: Fwhh
}X gzSS
}X gzSS
;J ^V0^SPV
;J ^V0^SPV
m; y}v
m; y}v
1N EII
1N EII
*3 Qj*
*3 Qj*
z5*b -TT
z5*b -TT
Q$ (r1x1 ~K#]J#8!&z*#K /_ZbW`XBr_F^
Q$ (r1x1 ~K#]J#8!&z*#K /_ZbW`XBr_F^
Ac 8L*Z_ N/sN !]979
Ac 8L*Z_ N/sN !]979
Zi&?& GH[{ 7J^B9#t5J9J^
Zi&?& GH[{ 7J^B9#t5J9J^
yZ h,M WO@7s MaalU(
yZ h,M WO@7s MaalU(
4^^^e8e
4^^^e8e
tW k0MyM
tW k0MyM
LVg m\)S)
LVg m\)S)
AG \KZXX
AG \KZXX
~c 07Zb% D2Q
~c 07Zb% D2Q
Qy 9$7se 4sL
Qy 9$7se 4sL
:l%%[}7%w q?
:l%%[}7%w q?
gl%k2
%hh }A0m,m
r
r
V
V
I
I
-sqtfp w5@8
$~~ &)5tg
6f-`1 :[_JA0
6f-`1 :[_JA0
OPQEP
OPQEP
%i eINI
%i eINI
CB [E@Efjf
CB [E@Efjf
F|R|/F/
F|R|/F/
dY RN5N
dY RN5N
\W RRH H-P_/h cQ/F
\W RRH H-P_/h cQ/F
(IIUUII
(IIUUII
&D
&D
?I? Jz
?I? Jz
)w) ]72
)w) ]72
2x 1\3
2x 1\3
5V5 T)7
5V5 T)7
F{F )~xJ~ rWCC NfRuu
F{F )~xJ~ rWCC NfRuu
{GESfBvF(R l2!Ll!6 GcYKss EC4A=SCSbAfq
{GESfBvF(R l2!Ll!6 GcYKss EC4A=SCSbAfq
+V sSSᵃ
+V sSSᵃ
o@o 4N
o@o 4N
aza CUU
aza CUU
h0 D%%VG%%†
h0 D%%VG%%†
o&o ww ,MM4 lN**X*^u
o&o ww ,MM4 lN**X*^u
y|+i|\a
y|+i|\a
8,f;?? Y`?t1j`jzt_,
8,f;?? Y`?t1j`jzt_,
2SV@HH U{w$F&{&k$n-†
2SV@HH U{w$F&{&k$n-†
rSr aps ~]n aya -ii
rSr aps ~]n aya -ii
*k* O-r
*k* O-r
BCB [wZqw
BCB [wZqw
]g\idgl ZQZ;]%v(om D4YyvUYm@ya
]g\idgl ZQZ;]%v(om D4YyvUYm@ya
?Y$Y( Y=;!R6y6M
?Y$Y( Y=;!R6y6M
M88Zl`v`&L X?=qE sgG|teetCshg
M88Zl`v`&L X?=qE sgG|teetCshg
;m]6*JT6J fNf X7fz~~
;m]6*JT6J fNf X7fz~~
@G jPpU7 p(X\X
@G jPpU7 p(X\X
SW zJ ;7cHc
SW zJ ;7cHc
f?p, _GO9O
f?p, _GO9O
&ISg^JX &C0)0
&ISg^JX &C0)0
e& ++^^
e& ++^^
7: Fwhh
7: Fwhh
}X gzSS
}X gzSS
;J ^V0^SPV
;J ^V0^SPV
m; y}v
m; y}v
1N EII
1N EII
*3 Qj*
*3 Qj*
z5*b -TT
z5*b -TT
Q$ (r1x1 ~K#]J#8!&z*#K /_ZbW`XBr_F^
Q$ (r1x1 ~K#]J#8!&z*#K /_ZbW`XBr_F^
Ac 8L*Z_ N/sN !]979
Ac 8L*Z_ N/sN !]979
Zi&?& GH[{ 7J^B9#t5J9J^
Zi&?& GH[{ 7J^B9#t5J9J^
yZ h,M WO@7s MaalU(
yZ h,M WO@7s MaalU(
4^^^e8e
4^^^e8e
tW k0MyM
tW k0MyM
LVg m\)S)
LVg m\)S)
AG \KZXX
AG \KZXX
~c 07Zb% D2Q
~c 07Zb% D2Q
Qy 9$7se 4sL
Qy 9$7se 4sL
:l%%[}7%w q?
:l%%[}7%w q?
gl%k2
%hh }A0m,m
r
r
V
V
I
I
U\s7\R-I
Rb_BA_B U#|O Kx rm}mC8+R
gl%k2
#0#lb(!ji† O 082/^ ~De~&~VU!
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
CeClQ^8^g† p %g\_Ii^ kmdkRk1Tn
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
$r41W0o† & g}g|0e L5l
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
k%ow3Hd† ] m*Gg 4 F3a 4{?c
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
s;sfsP5,, _ (o3v O {D{oo SNZL
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
lUlBlFHHS W +]BQ U =\sua @eY+
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
;\;q*FyM N T+e,I ob%Vb~4
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
h]T5Pzz G yOr &;L
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
OeI?Z`@ek`F⁷ ~ #ap2Ar P T%s *{lz
OPQEP
r
%sux/^rxxs3
OPQEP
#+TI+9+u+$⁶ J {;;V ` d_@ yuLq
%i eINI
V
%sux/^rxxs3
%i eINI
CB [E@Efjf
V
%sux/^rxxs3
CB [E@Efjf
F|R|/F/
V
%sux/^rxxs3
F|R|/F/
dY RN5N
I
%sux/^rxxs3
dY RN5N
bmJIxmVIR X wy?w cHc Hz]HsH`h8
\W RRH H-P_/h cQ/F
V
%sux/^rxxs3
\W RRH H-P_/h cQ/F
D_D2GEu-- p JJ|K 9aL
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
j5jMNi$+N + ;[{ζ r{8rSrmpC
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
*E*GLWJoW B F,Qr ydy6cd!
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
e!e^:_(L( O A$:O @k~@0@ez;
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
[-f@H!@r]f]H L vWC WOmW4WC|g
(IIUUII
V
%sux/^rxxs3
(IIUUII
&D
V
%sux/^rxxs3
&D
?I? Jz
V
%sux/^rxxs3
?I? Jz
)w) ]72
V
%sux/^rxxs3
)w) ]72
2x 1\3
V
%sux/^rxxs3
2x 1\3
5V5 T)7
I
%sux/^rxxs3
5V5 T)7
F{F )~xJ~ rWCC NfRuu
I
%sux/^rxxs3
F{F )~xJ~ rWCC NfRuu
{GESfBvF(R l2!Ll!6 GcYKss EC4A=SCSbAfq
I
%sux/^rxxs3
{GESfBvF(R l2!Ll!6 GcYKss EC4A=SCSbAfq
qk9ckTkH]+e B :,nY un:uAuR)F
+V sSSᵃ
V
%sux/^rxxs3
+V sSSᵃ
o@o 4N
I
%sux/^rxxs3
o@o 4N
aza CUU
I
%sux/^rxxs3
aza CUU
5V5 T)7
I
%sux/^rxxs3
5V5 T)7
h0 D%%VG%%†
I
%sux/^rxxs3
h0 D%%VG%%†
o&o ww ,MM4 lN**X*^u
r
%sux/^rxxs3
o&o ww ,MM4 lN**X*^u
y|+i|\a
r
%sux/^rxxs3
y|+i|\a
8,f;?? Y`?t1j`jzt_,
r
%sux/^rxxs3
8,f;?? Y`?t1j`jzt_,
@R@`Zddja 8 OiR QqWQ
8,f;?? Y`?t1j`jzt_,
r
%sux/^rxxs3
8,f;?? Y`?t1j`jzt_,
2SV@HH U{w$F&{&k$n-†
r
%sux/^rxxs3
2SV@HH U{w$F&{&k$n-†
rSr aps ~]n aya -ii
I
%sux/^rxxs3
rSr aps ~]n aya -ii
T;TGWb--= p U$E4 o`- /MR% d2\dBd|&z
8,f;?? Y`?t1j`jzt_,
r
%sux/^rxxs3
8,f;?? Y`?t1j`jzt_,
RW`[l[Ww:%@; 5 ?q%` X0[
*k* O-r
V
%sux/^rxxs3
*k* O-r
!QvcI!Qv:(C { u/(/u bNh
BCB [wZqw
r
%sux/^rxxs3
BCB [wZqw
[-f@H!@r]f]H L vWC WOmW4WC|g
]g\idgl ZQZ;]%v(om D4YyvUYm@ya
V
%sux/^rxxs3
]g\idgl ZQZ;]%v(om D4YyvUYm@ya
?Y$Y( Y=;!R6y6M
I
%sux/^rxxs3
?Y$Y( Y=;!R6y6M
(t(%54Nh4 4 yF=/S -#)-
M88Zl`v`&L X?=qE sgG|teetCshg
r
%sux/^rxxs3
M88Zl`v`&L X?=qE sgG|teetCshg
BBu!ZyM@!@Z+¹ ? +^I h DOJU ^J+j
;m]6*JT6J fNf X7fz~~
I
%sux/^rxxs3
;m]6*JT6J fNf X7fz~~
RW`[l[Ww:%@; 5 ?q%` X0[
@G jPpU7 p(X\X
V
%sux/^rxxs3
@G jPpU7 p(X\X
SW zJ ;7cHc
V
%sux/^rxxs3
SW zJ ;7cHc
f?p, _GO9O
V
%sux/^rxxs3
f?p, _GO9O
&ISg^JX &C0)0
V
%sux/^rxxs3
&ISg^JX &C0)0
CB [E@Efjf
V
%sux/^rxxs3
CB [E@Efjf
e& ++^^
V
%sux/^rxxs3
e& ++^^
7: Fwhh
V
%sux/^rxxs3
7: Fwhh
}X gzSS
V
%sux/^rxxs3
}X gzSS
;J ^V0^SPV
V
%sux/^rxxs3
;J ^V0^SPV
m; y}v
V
%sux/^rxxs3
m; y}v
1N EII
V
%sux/^rxxs3
1N EII
*3 Qj*
V
%sux/^rxxs3
*3 Qj*
z5*b -TT
I
%sux/^rxxs3
z5*b -TT
Q$ (r1x1 ~K#]J#8!&z*#K /_ZbW`XBr_F^
r
%sux/^rxxs3
Q$ (r1x1 ~K#]J#8!&z*#K /_ZbW`XBr_F^
!QvcI!Qv:(C { u/(/u bNh
Ac 8L*Z_ N/sN !]979
V
%sux/^rxxs3
Ac 8L*Z_ N/sN !]979
Zi&?& GH[{ 7J^B9#t5J9J^
r
%sux/^rxxs3
Zi&?& GH[{ 7J^B9#t5J9J^
`SL=[BVG² A s7]w 9oO9Z9&BN
yZ h,M WO@7s MaalU(
r
%sux/^rxxs3
yZ h,M WO@7s MaalU(
~\~;FHH)M p SLFr e]seTeg;l
yZ h,M WO@7s MaalU(
r
%sux/^rxxs3
yZ h,M WO@7s MaalU(
wi\Q5n!B³ M 7=VP WkR
yZ h,M WO@7s MaalU(
r
%sux/^rxxs3
yZ h,M WO@7s MaalU(
}@}@~gOZ Z w9Dk A$c
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0
!:!Mbb)⁴ e ];~0 pOA
4^^^e8e
I
%sux/^rxxs3
4^^^e8e
e& ++^^
I
%sux/^rxxs3
e& ++^^
TpvMl&&Kᵇ ] %n C[XT&_c(&[_4
tW k0MyM
I
%sux/^rxxs3
tW k0MyM
&ISg^JX &C0)0
I
%sux/^rxxs3
&ISg^JX &C0)0
LVg m\)S)
I
%sux/^rxxs3
LVg m\)S)
AG \KZXX
I
%sux/^rxxs3
AG \KZXX
tJs\|JfJPJl⁵ Y fV_) 8C(&
~c 07Zb% D2Q
I
%sux/^rxxs3
~c 07Zb% D2Q
Qy 9$7se 4sL
V
%sux/^rxxs3
Qy 9$7se 4sL
SgSw*11= x {ir2 R\}
:l%%[}7%w q?
I
%sux/^rxxs3
:l%%[}7%w q?
prp,oWIfW E HX~/ [J*[0[d2!
6f-`1 :[_JA0
r
%sux/^rxxs3
6f-`1 :[_JA0

bw ~; :M90OT0C FFFL

rAmgen collaboration; BeiGene has China commercial rights. IEnsem collaboration; BeiGene has global rights. VDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. TLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. BZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. @Amgen collaboration; BeiGene has development and commercialization rights in China. rAmgen collaboration; BeiGene has development and commercialization rights in China. uIn combination with Zanubrutinib. rMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. † Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Please login or register for full access

Register

Already registered?  Login